LEO Pharma and ICON to scale clinical trial within medical dermatology

LEO Pharma and ICON (NASDAQ:ICLR) enter a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective.
This will aid LEO’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.
“We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient. Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility. ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy building on driving innovation through partnerships and support staying competitive.” said Jörg Möller, executive VP and head of Global R&D at LEO Pharma.